Skip to content
TriangleGet started
← Full study record

NCT00866047 · OUTCOME

Objective Response Rate by Independent Review Group

A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma · Source last updated 2017-03-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percent of participants
Interval / dispersion
95% Confidence Interval
Time frame
up to 12 months

What was measured

Percentage of participants who achieved a best response of complete remission (CR, disappearance of all evidence of disease) or partial remission (PR, regression of greater than or equal to 50% of measurable disease and no new sites) per Cheson 2007 Revised Response Criteria for Malignant Lymphoma.

Analysis population: Intention to treat

Groups in this outcome

Brentuximab Vedotin

Brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Brentuximab Vedotin58

Reported measurements

Source class 1
Values in percent of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Brentuximab Vedotin86Not reported74.693.9Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        74.6
        upper Limit
        93.9
        value
        86
denoms
  1. counts
    1. group Id
      OG000
      value
      58
    units
    Participants
description
Percentage of participants who achieved a best response of complete remission (CR, disappearance of all evidence of disease) or partial remission (PR, regression of greater than or equal to 50% of measurable disease and no new sites) per Cheson 2007 Revised Response Criteria for Malignant Lymphoma.
dispersion Type
95% Confidence Interval
groups
  1. description
    Brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion
    id
    OG000
    title
    Brentuximab Vedotin
param Type
NUMBER
population Description
Intention to treat
reporting Status
POSTED
time Frame
up to 12 months
title
Objective Response Rate by Independent Review Group
type
PRIMARY
unit Of Measure
percent of participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Independent clinical review pending · Not medical advice